Ascendis Pharma A/S Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ascendis Pharma A/S stock.
View analyst ratings for Ascendis Pharma A/S or view top-rated stocks.

Wall Street analysts have given Ascendis Pharma A/S a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ascendis Pharma A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Tuesday, May 18th 2021.
View our earnings forecast for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings data on Tuesday, March, 9th. The biotechnology company reported ($2.64) earnings per share for the quarter, missing the consensus estimate of ($1.84) by $0.80. The biotechnology company earned $0.64 million during the quarter, compared to analyst estimates of $2.71 million. Ascendis Pharma A/S had a negative net margin of 4,042.79% and a negative trailing twelve-month return on equity of 55.72%.
View Ascendis Pharma A/S's earnings history.

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ASND shares have increased by 10.4% and is now trading at $130.83.
View which stocks have been most impacted by COVID-19.

11 brokers have issued 1 year price targets for Ascendis Pharma A/S's stock. Their forecasts range from $154.00 to $216.00. On average, they expect Ascendis Pharma A/S's stock price to reach $192.22 in the next year. This suggests a possible upside of 46.9% from the stock's current price.
View analysts' price targets for Ascendis Pharma A/S or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ascendis Pharma A/S include Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), Genmab A/S (GMAB), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), CureVac (CVAC), Horizon Therapeutics Public (HZNP), Catalent (CTLT), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Elanco Animal Health (ELAN) and Ono Pharmaceutical (OPHLF).
View all of ASND's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Ascendis Pharma A/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Henry James International Management Inc. (0.07%), Zeke Capital Advisors LLC (0.00%) and Private Ocean LLC (0.00%).

ASND stock was sold by a variety of institutional investors in the last quarter, including Henry James International Management Inc..

ASND stock was purchased by a variety of institutional investors in the last quarter, including Private Ocean LLC, and Zeke Capital Advisors LLC.

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ASND stock can currently be purchased for approximately $130.83.

Ascendis Pharma A/S has a market capitalization of $7.03 billion and generates $14.98 million in revenue each year. The biotechnology company earns $-244,180,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis.

Ascendis Pharma A/S employs 482 workers across the globe.

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

Ascendis Pharma A/S is headquartered at TUBORG BOULEVARD 12, HELLERUP G7, DK-2900.

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]